ODDITY to Announce Third Quarter 2026 Financial Results on November 11, 2026GlobeNewsWire • Wednesday
Oddity Tech (ODD) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 10/15/26
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory RecognitionGlobeNewsWire • 09/28/26
Earnings Estimates Moving Higher for Oddity Tech (ODD): Time to Buy?Zacks Investment Research • 09/15/26
ODDITY Tech Reports Second Quarter 2026 Results, Expects Sequential Revenue Improvement in the Third QuarterGlobeNewsWire • 09/09/26
5 microcap software stocks expected to soar by triple digits as the companies' sales popMarket Watch • 07/30/26
ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026GlobeNewsWire • 07/22/26
ODDITY Tech Reports First Quarter 2026 Results, Makes Progress Toward NormalizationGlobeNewsWire • 06/02/26
ODD 9-DAY DEADLINE ALERT: ODDITY Tech. (ODD) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action - Hagens BermanPRNewsWire • 05/11/26
ODD DEADLINE ALERT: Hagens Berman Alerts ODDITY Tech. (ODD) Investors to Today's Lead Plaintiff Deadline in Securities Class ActionPRNewsWire • 05/11/26
ODDITY DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ODDITY Tech Ltd. Investors to Secure Counsel Before Important May 11 Deadline in Securities Class Action - ODDNewsfile Corp • 05/11/26
Bronstein, Gewirtz & Grossman LLC Urges ODDITY Tech Ltd. Investors to Act: Class Action Filed Alleging Investor HarmNewsfile Corp • 05/11/26